Alan Palkowitz, PhD, CEO & President, IBRI
We were pleased to announce the arrival of our new leader, Alan Palkowitz, PhD, in September 2020.
Chairman of the Board of Directors Daniel Evans, Jr., said, “Having spent time in industry and academia, Alan understands the many opportunities for collaboration to improve the lives of Hoosiers. He shares our passion for translational research and our vision to build a world-class organization that catalyzes activities across the life sciences ecosystem.”
Dr. Palkowitz maintains his role at the Indiana University (IU) School of Medicine as a senior research professor of medicine, where he directs the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center. He also is a key contributor to the IU Precision Health Initiative.
Prior to joining the IU School of Medicine, Dr. Palkowitz served as the vice president of Discovery Chemistry Research and Technologies at Eli Lilly and Company. In his role, he was responsible for the global small molecule drug discovery strategy and delivery of clinical candidates in disease areas including diabetes, oncology, immunology and neurodegenerative disorders.
Dr. Palkowitz has worked with the Board of Directors and leadership team to design a new strategic direction for the IBRI. He knows that to truly shape the future of translational science we must transform to achieve ambitious goals.